Does Adc Therapeutics SA (ADCT) Stock have plenty of room for growth?
Guggenheim raised the price target for the Adc Therapeutics SA (NYSE:ADCT) stock to “a Buy”. The rating was released on March 28, 2024, according to finviz. The research report from BofA Securities has downgraded the stock from Neutral to Underperform, with a price target set at $2. The stock was initiated by CapitalOne, who disclosed […]
Stay away from Adc Therapeutics SA (ADCT) Stock or get into it
Guggenheim raised the price target for the Adc Therapeutics SA (NYSE:ADCT) stock to “a Buy”. The rating was released on March 28, 2024, according to finviz. The research report from BofA Securities has downgraded the stock from Neutral to Underperform, with a price target set at $2. The stock was initiated by CapitalOne, who disclosed […]
Adc Therapeutics SA (ADCT) Stock is poised for a successful quarter
Guggenheim raised the price target for the Adc Therapeutics SA (NYSE:ADCT) stock to “a Buy”. The rating was released on March 28, 2024, according to finviz. The research report from BofA Securities has downgraded the stock from Neutral to Underperform, with a price target set at $2. The stock was initiated by CapitalOne, who disclosed […]
Where are Investors’ Sentiments? Adc Therapeutics SA (ADCT) Stock
Guggenheim raised the price target for the Adc Therapeutics SA (NYSE:ADCT) stock to “a Buy”. The rating was released on March 28, 2024, according to finviz. The research report from BofA Securities has downgraded the stock from Neutral to Underperform, with a price target set at $2. The stock was initiated by CapitalOne, who disclosed […]
Trading Adc Therapeutics SA (ADCT) Stock is a good strategy
JP Morgan raised the price target for the Adc Therapeutics SA (NYSE:ADCT) stock from “an Underweight” to “a Neutral”. The rating was released on August 10, 2023, according to finviz. We previously noted in another research note published on April 24, 2023 by BofA Securities that downgraded the stock from a Neutral to an Underperform […]
